(2S)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid | 58810-15-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid
• 英文别名: Boc-Ser-Pro-OH；L-Proline, 1-[N-[(1,1-dimethylethoxy)carbonyl]-L-seryl]-；(2S)-1-[(2S)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]pyrrolidine-2-carboxylic acid
• CAS: 58810-15-4
• 化学式: C₁₃H₂₂N₂O₆
• 分子量: 302.327
• InChiKey: JAYOUDXNUKOVLR-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Boc-Ser-Pro-OMe 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以33%的产率得到(2S)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  [EN] STAT DEGRADERS AND USES THEREOF
  [FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用相同的方法。

  公开号：

  WO2021188696A1

文献信息

• METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES
  申请人：Kelner, Michael

  公开号：EP3667323A1

  公开（公告）日：2020-06-17

  The present invention relates to compositions, methods and devices for treating cancer with illudofulvenes including methods to detect the expression levels of genes encoding biomarkers in cancer patients and to predict the responsiveness of cancer patients to illudofulvenes.

  本发明涉及用紫杉醇治疗癌症的组合物、方法和装置，包括检测癌症患者体内编码生物标志物的基因表达水平和预测癌症患者对紫杉醇反应性的方法。
• Preparation and biological evaluation of key fragments and open analogs of scleritodermin A
  作者：Diver Sellanes、Francisco Campot、Ivana Núñez、Gerardo Lin、Pablo Espósito、Sylvia Dematteis、Jenny Saldaña、Laura Domínguez、Eduardo Manta、Gloria Serra

  DOI：10.1016/j.tet.2010.05.040

  日期：2010.7

  The synthesis of key fragments of scleritodermin A. their assembly, and their biological evaluation as cytotoxic and anthelmintic were performed. Highlights of the synthetic route include formation of the alpha-ketoamide linkage and use of stereocontrolled reactions. Open analogs of this natural product were obtained using a convergent strategy. (C) 2010 Elsevier Ltd. All rights reserved.
• AFFINITY MEDICANT CONJUGATE
  申请人：AF Chemicals, LLC

  公开号：US20210299063A1

  公开（公告）日：2021-09-30

  In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.
• [EN] STAT DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2021188696A1

  公开（公告）日：2021-09-23

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。